More Efficient Tools to Realize Information for Consumers Act

Bill: 116-hr-2296
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Introduced: 2019-04-12 in the House
Policy area: Health
Subjects: Civil actions and liability
Congressional oversight
Consumer affairs
Corporate finance and management
Government information and archives
Government studies and investigations
Inflation and prices
Medical research
Prescription drugs
Research and development

Summary:
action_date: 2019-04-12
text: 

Fair Accountability and Innovative Research Drug Pricing Act of 2019 or the FAIR Drug Pricing Act of 2019

 
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.

action_date: 2019-09-24
text: 

More Efficient Tools to Realize Information for Consumers Act or the METRIC Act

 
 This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain. Specifically, HHS must publish reports submitted by drug manufacturers that include the percentage of any wholesale drug price increase that is greater than 10% in one calendar year (or 25% over three consecutive years), an explanation for the price increase, and other data. HHS must enter agreements with other agencies, research organizations, and public and private health insurers to share data submitted to HHS by drug manufacturers about the identity and quantity of drug sample requests by health practitioners.
 
 HHS also must publish online aggregate data reported by pharmacy benefits managers (PBMs), including the percentage of prescriptions provided by mail-order, rate that generic versions of drugs are dispensed, and aggregate discounts, rebates, or price concessions negotiated.
 
 The bill requires the Federal Trade Commission to report about potentially anticompetitive practices by PBMs such as steering patients to certain pharmacies or designing price formulas that increase the market share of higher priced drugs, among other information. The report also must include recommendations to increase transparency and deter anticompetitive behavior.
 
 The bill further requires Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that provides prescribers with patient-specific formulary and benefit information. Additionally, the bill expands certain price reporting requirements for prescription drug payments under Medicare.


Legislative actions:
action_date: 2019-09-24
text: Placed on the Union Calendar, Calendar No. 170.
action_date: 2019-09-24
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-215.
action_date: 2019-09-24
text: Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-215.
action_date: 2019-07-17
text: Ordered to be Reported (Amended) by Voice Vote.
action_date: 2019-07-17
text: Committee Consideration and Mark-up Session Held.
action_date: 2019-07-11
text: Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
action_date: 2019-07-11
text: Subcommittee Consideration and Mark-up Session Held.
action_date: 2019-05-21
text: Subcommittee Hearings Held.
action_date: 2019-04-15
text: Referred to the Subcommittee on Health.
action_date: 2019-04-12
text: Referred to the House Committee on Energy and Commerce.
action_date: 2019-04-12
text: Introduced in House
action_date: 2019-04-12
text: Introduced in House